AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
February 19, 2021
-
February 18, 2021
-
February 10, 2021- Collaboration leverages Caribou's next-generation CRISPR genome editing technology platform and AbbVie's antigen-specific binders
-
February 10, 2021-- Children living with neurogenic detrusor overactivity who are not adequately managed with anticholinergic medication now have a new treatment option prior to surgical intervention
-
February 03, 2021- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56
-
January 26, 2021NEW TECHNOLOGY ALLOWS FOR THE TREATMENT OF TWO AREAS OF FAT AT ONCE AND NEW ELITE APPLICATORS DESIGNED FOR IMPROVED FIT AND COMFORT
-
January 25, 2021- RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2]
-
January 15, 2021- BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications
-
January 12, 2021-- Agreement Includes Development of Xact Device, a Minimally-Invasive Alternative Option for Performing Face and Neck Lifts --
-
January 07, 2021- A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab (600 mg or 1200 mg) achieved both primary endpoints, demonstrating statistically significant results for clinical remission and endoscopic response at week 12 compared to placebo[1,2]
-
January 05, 2021- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo (p<0.001)[1]
-
December 23, 2020- Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM
-
December 11, 2020- Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoid arthritis (RA)[1-4]
-
December 10, 2020- 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1]
-
December 09, 2020- Significantly more upadacitinib-treated (45 mg) patients achieved clinical remission (primary endpoint per Adapted Mayo Score) at week 8 compared to placebo in adults with moderate to severe ulcerative colitis[1]
-
December 05, 2020- New five-year, follow-up analysis from the Phase 3 MURANO trial shows median progression-free survival (PFS) of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab compared to 17.0 months in patients taking bendamustine plus rituximab (BR) after three years or more off treatment[1]
-
December 02, 2020- Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases
-
December 01, 2020
-
November 16, 2020NUMBER 1 SELLING PRODUCT OF ITS KIND CELEBRATES BOTH LOYAL AND NEW CONSUMERS WITH EXCLUSIVE OFFER ON NOVEMBER 18th
-
November 12, 2020
-
November 05, 2020- Nearly 40 abstracts on eight investigational and approved products across 11 cancer types to be presented
-
October 30, 2020- Reports Third-Quarter Diluted EPS of $1.29 on a GAAP Basis; Adjusted Diluted EPS of $2.83
-
October 29, 2020-- New RINVOQ analyses from the Measure Up 1 and 2 monotherapy studies show improvements in additional measures of skin clearance, itch and quality of life in adult and adolescent patients with moderate to severe atopic dermatitis[1]
-
October 28, 2020- Researchers to share updates on long-term safety and efficacy of RINVOQ for the treatment of moderate to severe rheumatoid arthritis
-
October 28, 2020- Presbyopia is a common, progressive condition that reduces the aging eye's ability to focus on near objects and affects nearly four out of 10 people in the U.S.
-
October 19, 2020- In three pivotal Phase 3 studies, RINVOQ met co-primary and all secondary endpoints in adult and adolescent patients with moderate to severe atopic dermatitis[1-3]
-
October 16, 2020- The FDA approval of VENCLEXTA for newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a series of trials including two Phase 3 trials - VIALE-A (M15-656) and VIALE-C (M16-043)
-
October 07, 2020-- Acquisition Immediately Enhances Allergan Aesthetics' Leading International Dermal Filler Portfolio & Pipeline --
-
October 06, 2020
-
October 02, 2020- New data from Phase 3 ADVANCE trial evaluating investigational medicine atogepant for the preventive treatment of migraine accepted for oral presentation
-
September 28, 2020- Elezanumab (ABT-555) is an investigational treatment being evaluated in neurological disorders, including treatment following spinal cord injury
September 16, 2020Partnership will educate on body contouring options and encourage consumers to "Shape Your Moment" with CoolSculpting®-
September 11, 2020- Final data from the 12-week DYSCOVER study, the first randomized trial of DUODOPA® (levodopa/carbidopa intestinal gel) on the duration and severity of dyskinesia in patients with advanced Parkinson's disease
-
September 11, 2020
-
September 04, 2020AbbVie and I-Mab to collaborate on development and commercialization of I-Mab's highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)
-
September 03, 2020
-
August 25, 2020- RINVOQ demonstrated significant improvements to signs and symptoms of active ankylosing spondylitis[1]
-
August 12, 2020- Data from Phase 3 VIALE-A study showed venetoclax plus azacitidine reduced the risk of death by 34% compared to azacitidine plus placebo in newly-diagnosed patients with AML who are ineligible for chemotherapy
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
